Skip to main content
SpringerLink
Log in

Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromsø study 2001

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective: The beneficial effect of lipid-lowering drugs (LLDs) is well documented. Despite increasing sales of LLDs, little is known about what characterizes LLD users. Our objective was to describe LLD users in a general population according to socio-demographic factors, cardiovascular risk factors and coronary heart disease (CHD), and to study the achievement of cholesterol treatment goals according to national guidelines. Methods: The Tromsø study is a population-based study of chronic diseases, risk factors and drug use in the municipality Tromsø, in north Norway. The fifth survey was conducted in 2001 and included 7,973 men and women (attendance rate 78.1%). Self-reported use of LLDs and/or proprietary LLDs was included as LLD use in the analysis. Results: LLD use was reported in 9.6% of all women and 14.0% of all men, of whom 36.5% achieved the nationally recommended lipid goal. Among individuals with CHD, 49.9% of all women and 55.4% of all men were LLD users. The individuals with a risk condition (hypertension and/or diabetes) and total cholesterol level above the target of 5.0 mmol/l and the healthy individuals with total cholesterol level ≥8.0 mmol/l constituted 47.2% of the study population without CHD. In this group, which was eligible for primary prevention, 8.0% of the women and 7.4% of the men reported LLD use. Conclusions: Only half of all subjects with CHD were taking a LLD. The large discrepancy between national recommendations and actual LLD use in primary prevention should be addressed in future revisions of the guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344:1383–1389

    Google Scholar 

  2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335:1001–1009

    Article  CAS  PubMed  Google Scholar 

  3. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–1357

    Google Scholar 

  4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301–1307

    Article  CAS  PubMed  Google Scholar 

  5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 279:1615–1622

    Article  CAS  PubMed  Google Scholar 

  6. Wesenberg G (ed) (2000) Treatment recommendations for hyperliperlipidemia. Norwegian Medicines Agency, Oslo

    Google Scholar 

  7. Pedersen JI, Tverdal A, Kirkhus B (2004) Diet and the rise and fall of cardiovascular disease mortality in Norway. Tidsskr Nor Laegeforen 124:1532–1536

    PubMed  Google Scholar 

  8. Rønning M (2003) Drug Consumption in Norway 1998–2002. WHO collaborating centre for drug statistics and methodology, Oslo

    Google Scholar 

  9. Nordic Medico-Statistical Committee (NOMESCO) (2003) Health statistics in the nordic countries 2001. NOMESCO, Copenhagen

  10. Dubois RW, Alexander CM, Wade S, Mosso A, Markson L, Lu JD et al (2002) Growth in use of lipid-lowering therapies: are we targeting the right patients? Am J Manag Care 8:862–867

    PubMed  Google Scholar 

  11. Savoie I, Kazanjian A (2002) Utilization of lipid-lowering drugs in men and women. A reflection of the research evidence? J Clin Epidemiol 55:95–101

    Article  PubMed  Google Scholar 

  12. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U (1997) Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 53:185–189

    Article  CAS  PubMed  Google Scholar 

  13. Svilaas A, Thoresen M, Kristoffersen JE, Hjartaaker J, Westheim A (2000) How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. Scand J Prim Health Care 18:232–236

    Article  CAS  PubMed  Google Scholar 

  14. Notø AT, Steffensen L, Nordøy A, Hansen JB (2001) Use of statins in hospitals after myocardial infarction. Tidsskr Nor Laegeforen 121:2467–2471

    PubMed  Google Scholar 

  15. EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22:554–572

    Article  PubMed  Google Scholar 

  16. Abookire SA, Karson AS, Fiskio J, Bates DW (2001) Use and monitoring of ‘statin’ lipid-lowering drugs compared with guidelines. Arch Intern Med 161:53–58

    Article  CAS  PubMed  Google Scholar 

  17. Primatesta P, Poulter NR (2000) Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 321:1322–1325

    Article  CAS  PubMed  Google Scholar 

  18. Reid FD, Cook DG, Whincup PH (2002) Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 88:15–19

    Article  CAS  PubMed  Google Scholar 

  19. Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS et al (1998) Time trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health study. Arch Intern Med 158:1761–1768

    Article  CAS  PubMed  Google Scholar 

  20. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J (1998) Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 82:61–65

    Article  CAS  PubMed  Google Scholar 

  21. Municipal administration of Tromsø (ed) (1996) Figures and facts (Kalde tall og harde fakta). Tromsø, Norway

  22. Engstad T, Bønaa KH, Viitanen M (2000) Validity of self-reported stroke: The Tromsø Study. Stroke 31:1602–1607

    CAS  PubMed  Google Scholar 

  23. Wilsgaard T (2002) Longitudinal analysis of cardiovascular risk factors. Thesis, University of Tromsø, Tromsø

  24. World Health Organization (1997) Obesity. Preventing and managing the global epidemic. Report of a WHO consultation on obesity. WHO, Geneva

  25. Friedewald W, Levy R, Frederickson D (1997) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultra-centrifuge. Clin Chem 18:499–501

    Google Scholar 

  26. World Health Organization (1999) International society of hypertension guidelines for the management of hypertension (Guidelines subcommittee). J Hypertens 17:151–183

    Article  PubMed  Google Scholar 

  27. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462–467

    Article  PubMed  Google Scholar 

  28. Svilaas A, Risberg K, Thoresen M, Ose L (2000) Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol 86:1250–1253

    Article  CAS  PubMed  Google Scholar 

  29. Hippisley-Cox J, Cater R, Pringle M, Coupland C (2003) Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 326:689–694

    Article  CAS  PubMed  Google Scholar 

  30. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582–587

    Article  CAS  PubMed  Google Scholar 

  31. Barter PJ, O’Brien RC (2000) Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis 149:199–205

    Article  CAS  PubMed  Google Scholar 

  32. Midthjell K, Holmen J, Bjørndal A, Lund Larsen G (1992) Is questionnaire information valid in the study of a chronic disease such as diabetes? The Nord-Trøndelag diabetes study. J Epidemiol Community Health 46:537–542

    CAS  PubMed  Google Scholar 

  33. Tretli S, Lund Larsen PG, Foss OP (1982) Reliability of questionnaire information on cardiovascular disease and diabetes: cardiovascular disease study in Finnmark county. J Epidemiol Community Health 36:269–273

    CAS  PubMed  Google Scholar 

  34. Kehoe R, Wu SY, Leske MC, Chylack LT Jr (1994) Comparing self-reported and physician-reported medical history. Am J Epidemiol 139:813–818

    CAS  PubMed  Google Scholar 

  35. Lampe FC, Walker M, Lennon LT, Whincup PH, Ebrahim S (1999) Validity of a self-reported history of doctor-diagnosed angina. J Clin Epidemiol 52:73–81

    Article  CAS  PubMed  Google Scholar 

  36. Paganini Hill A, Ross RK (1982) Reliability of recall of drug usage and other health-related information. Am J Epidemiol 116:114–122

    CAS  PubMed  Google Scholar 

  37. Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A (1999) Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci 21:217–220

    Article  CAS  PubMed  Google Scholar 

  38. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR et al (2001) Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 87:257–261

    Article  CAS  PubMed  Google Scholar 

  39. Lacy CR, Suh DC, Barone JA, Bueno M, Moylan D, Swartz C et al (2002) Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting. Arch Intern Med 162:468–473

    Article  PubMed  Google Scholar 

  40. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS et al (2002) A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med 162:1149–1155

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This project was funded by the University of Tromsø and the Norwegian Institute of Health. There is no conflict of interest and the authors have no relevant financial interest in this article.

Author information

Authors and Affiliations

  1. Institute of Pharmacy, University of Tromsø, 9037, Tromso, Norway

    Ingeborg Hartz, Anne Elise Eggen, Sameline Grimsgaard & Frode Skjold

  2. Institute of Community Medicine, University of Tromsø, 9037, Tromso, Norway

    Inger Njølstad

Authors
  1. Ingeborg Hartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Elise Eggen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sameline Grimsgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frode Skjold
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Inger Njølstad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ingeborg Hartz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hartz, I., Eggen, A.E., Grimsgaard, S. et al. Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromsø study 2001. Eur J Clin Pharmacol 60, 643–649 (2004). https://doi.org/10.1007/s00228-004-0827-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0827-z

Keywords

Search

Navigation